Can DRL’s new product launches offset the slowdown in Revlimid sales?
Published on: Oct. 27, 2025, 5:59 a.m. | Source: The Economic Times
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with valuations factoring in earnings upside.
